Quantcast

Novartis Issues R&D Update; Plans 60 Major Submissions From 2019 To 2021


Shutterstock photo

Novartis Issues R&D Update; Plans 60 Major Submissions From 2019 To 2021


(RTTNews.com) - Swiss drug major Novartis ( NVS ) on Monday issued its Research & Development update, highlighting its development pipeline including potential blockbusters and advanced therapy platforms. The company said 60 major submissions are planned from 2019 to 2021.

The company reported 26 potential blockbusters in confirmatory development. There are 13 projects in clinical development across Cell, Gene & Radioligand therapies, and 9 more are expected to enter the clinic in 2019.

Novartis said it is advancing a pipeline of medicines with potential to change the standard of care in high burden disease areas. In multiple sclerosis, Mayzent (siponimod, formerly BAF312) is expected to launch in Q1 2019 as the first and only drug proven to delay progression for typical patients living with SPMS.

Further, the company said maximizing the potential of in-line brands with new data is a key development priority. Novartis is pursuing new indications and building out the data profile for Cosentyx, Entresto and Gilenya.

Cosentyx is expected to be Novartis' largest drug next year, with robust growth in all three approved indications, PSO, PSA and AS. Confidence in Cosentyx comes from 100 studies and an extensive phase III clinical trial program, including PREVENT in non-radiographic axial spondyloarthropathy, a potential fourth indication.


Read the original article on RTTNews (http://www.rttnews.com/2951264/novartis-issues-r-d-update-plans-60-major-submissions-from-2019-to-2021.aspx)


For comments and feedback: contact editorial@rttnews.com




This article appears in: World Markets , Stocks , Economy , Commodities
Referenced Symbols: NVS



More from RTT News

Subscribe






See All RTT news











Research Brokers before you trade

Want to trade FX?